11/16/2026

340B and Medicaid: A Manufacturer's Guide to Duplicate Discount Risk and Disputes

The prohibition against duplicate discounts is a fundamental protection of the Medicaid Drug Rebate Program (“MDRP”) and the 340B Drug Pricing Program1. Manufacturers participating in the MDRP are not required  to provide both a discounted 340B price and a Medicaid rebate for  the same unit of utilization. However, identifying and preventing these duplicate discounts can be particularly challenging for claims processed through Managed Care Organizations (“MCOs”). 

For manufacturers, the challenge extends beyond determining whether a duplicate discount has occurred. Limited access to claim-level data, lack of detail in both chargeback and claim-level data, varying state Medicaid procedures, and fragmented oversight can make it difficult to identify affected claims, substantiate potential discrepancies, and recover rebates paid in error. This article examines the regulatory framework governing Medicaid duplicate discounts, the practical challenges manufacturers face, and the processes available to identify and address potential violations. 

Regulations and Requirements

Section 340B of the Public Health Service Act prohibits covered entities from requesting Medicaid payment for a 340B drug that is also subject to a Medicaid rebate. This prohibition applies to both Medicaid Fee-for-Service (“FFS”) and managed care utilization that comes through MCOs. For Medicaid FFS , HRSA's Medicaid Exclusion File (“MEF”) provides a way to identify covered entities that elect to use 340B-purchased drugs for Medicaid patients (“carve in”). 

Covered entities must report the applicable Medicaid provider identifiers and states in which they intend to bill Medicaid for 340B drugs. Those identifiers are used to help states and manufacturers distinguish rebate-eligible utilization from claims that could result in duplicate discounts..  The 2016 CMS Medicaid & CHIP Managed Care Final Rule requires states to include provisions in their managed care contracts directing plans to exclude 340B drug utilization from the data used for rebate invoicing (42 C.F.R. § 438.3(s)(3)), although no national claims-level exclusion mechanism currently exists. ²

Under its 2024 Medicaid Rebate Final Rule, CMS now requires states, through their managed care contracts, to instruct plans that cover outpatient drugs to assign and exclusively use a Medicaid-specific Rx Bank Identification Number (“BIN”)/Rx Processor Control Number (“PCN”) combination and group number on Medicaid pharmacy cards. However, manufacturers typically do not receive this data, which would make flagging Medicaid managed care claims easier at the pharmacy level. These identifiers stay on the pharmacy claim, and do not appear on state rebate invoices. Manufacturers typically do not receive these identifiers, even though they would make it easier to flag Medicaid managed care claims at the pharmacy level. 3 This lack of transparency creates substantial financial exposure for manufacturers.

Manufacturer Considerations

Manufacturers often must piece together information from Medicaid rebate invoices, utilization data, distribution records, chargeback activity, and available 340B purchasing information to identify potential discrepancies. These sources may not provide a complete or directly comparable view of individual transactions, making it difficult to establish where there is pricing and discount overlap.

This creates several areas of risk for manufacturers:

  • Manufacturers may pay Medicaid rebates on utilization that was already purchased at 340B prices, creating duplicate discounts.
  • Inconsistent state reporting and limited access to claim-level information can make it difficult to identify affected utilization and substantiate potential disputes.
  • Reconciling rebate claims against distribution, chargeback, and 340B purchasing information requires significant data analysis and coordination across internal teams and external stakeholders.
  • Differences in Medicaid billing procedures, reporting requirements, and dispute processes can complicate nationwide monitoring and resolution efforts. Without consistent monitoring and documentation, manufacturers may have difficulty evaluating financial exposure and supporting recovery efforts.

An additional consideration is the evolving state legislative landscape. An increasing number of states have enacted laws restricting manufacturers' ability to limit 340B contract pharmacy arrangements. Manufacturers should evaluate how these laws may affect distribution arrangements, data availability, compliance strategies, and duplicate discount investigations.

Given the differences between FFS and MCO utilization and data transparency, manufacturers should establish a repeatable process for identifying potential duplicate discounts and evaluating the associated financial exposure. This assessment should consider the available data and the specific requirements of the states in which the manufacturer operates.

  • Identify states with significant Medicaid managed care utilization and document how 340B claims are identified and excluded from manufacturer rebate invoices. Pay attention to the claim-level indicators, billing identifiers, and reporting requirements used by each state. 
    • For example, California requires a modifier (UD) on physician-administered drug claims. They also require a Basis of Cost Determination code of 08 on applicable pharmacy claims, and both of these fields are used to identify 340B utilization so the state excludes it from rebate invoicing. 4
    • New York requires 340B claim-level identifiers for both FFS and MCO claims, including a Submission Clarification Code (“SCC”) of 20 for applicable pharmacy claims. 5
  • Compare Medicaid rebate claims against 340B purchases (traditionally via chargeback data). Include other relevant data (i.e. 867 data) to identify potential overlap in utilization and 340B purchasing activity.
  • Review covered entities' Medicaid carve-in/carve-out status in the Medicaid Exclusion File for FFS utilization. While this alone is not enough to dispute a claim, it is one piece of the documentation that should be maintained.
  • Quantify potential rebate overpayments where sufficient information is available. Prioritize investigations based on estimated financial impact, strength of supporting evidence, frequency of identified discrepancies, and feasibility of pursuing recovery.

Once potential duplicate discounts have been identified and validated, manufacturers should determine the appropriate path for resolution. The available options depend on the source of the discrepancy, the parties involved, applicable state procedures, and the supporting evidence.

Manufacturers may dispute rebate invoices through the applicable state Medicaid agency when claims are believed to be ineligible for rebate due to 340B utilization. Manufacturers should obtain claim-level detail, identify disputed claims, provide supporting documentation, and follow the state’s established dispute and adjustment procedures.

Manufacturers may seek clarification directly from the covered entity regarding its Medicaid carve-in/carve-out elections, billing identifiers, and practices for identifying 340B utilization. 

Manufacturers may audit a covered entity when they have reasonable cause to believe it violated the duplicate discount or diversion prohibition. The audit follows HRSA's manufacturer audit guidelines, including HRSA review of the audit work plan and use of an outside auditor.  Audits may examine purchasing records, Medicaid billing practices, and controls designed to prevent duplicate discounts.

A completed audit is a prerequisite to a manufacturer's ADR claim. If evidence indicates covered entity noncompliance and good-faith efforts to resolve the dispute have been unsuccessful, manufacturers may consider pursuing a formal ADR under 42 C.F.R. Part 10. As discussed in Part 1 of this series, “A Manufacturer's Guide to the 340B ADR Process”, the ADR provides a process for resolving certain disputes between manufacturers and covered entities, but it is not a mechanism for raising rebate invoice disputes directly against state Medicaid agencies or MCOs.

Practical Recommendations

Preventing and addressing duplicate discounts requires more than investigating individual rebate discrepancies. Manufacturers benefit from establishing consistent processes to evaluate utilization, monitor potential exposure, document findings, and coordinate resolution across the organizations and external parties involved. The following practices can strengthen oversight and support the documentation needs for determining and resolving duplicate discounts. 

  • Assess the brand and organization’s exposure to duplicate discounts by monitoring your total Medicaid volume as well as your 340B volume. Pursuing duplicate discounts can be costly from both a financial and operational perspective. Typically if Medicaid and 340B volumes are under 10% of your total customer mix, the ROI metrics become difficult to overcome.
  • Establish routine analytics to identify potential duplicate discounts. Implement recurring analytics to identify potential duplicate discounts and evaluate trends in Medicaid rebate utilization.
  • Maintain detailed documentation supporting every disputed rebate claim. This may include data, calculations, and other records used to identify, validate and dispute potential duplicate discounts.
  • Document each state's dispute procedures, reporting requirements, and available data sources so investigations are consistent.
  • Coordinate government pricing, legal, compliance, rebate operations, and commercial contracting teams when evaluating potential exposure and determining potential resolution strategies.
  • Monitor evolving CMS guidance, HRSA policy, state legislation, and federal litigation that may affect duplicate discount prevention and manufacturers’ compliance obligations.

As Medicaid rebate requirements and 340B program oversight continue to evolve, manufacturers need reliable processes and accurate data to manage their pricing and rebate obligations. Woven Data partners with pharmaceutical manufacturers to manage the calculations, data, and workflows behind government pricing, government and commercial rebate processing, payment administration, and provide gross-to-net support. Our Managed Services provide the reliable operational support needed to navigate these complex responsibilities throughout the product lifecycle.

Footnotes
  1. 42 U.S.C. § 256b(a)(5)(A) (duplicate discount prohibition); HRSA Medicaid Exclusion File guidance.
  2. CMS Medicaid and CHIP Managed Care Final Rule, 81 Fed. Reg. 27498 (May 6, 2016); CMCS Informational Bulletin (2020) regarding prevention of duplicate discounts.
  3. Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (CMS-2434-F) (September 26, 2024)
  4. California DHCS website, “Frequently Asked Questions about Medi-Cal Drug Rebates”: https://www.dhcs.ca.gov/providers-partners/frequently-asked-questions-about-medi-cal-drug-rebates (last accessed 10/30/2026)
  5. New York State Medicaid Update - June 2023, Volume 39 - Number 11. “340B Claim Reminder for Covered Entities and Contract Pharmacies”: https://www.health.ny.gov/health_care/medicaid/program/update/2023/no11_2023-06 (last accessed 10/30/2026)

‍

‍

Talk to an Expert

Get Started